MA31798B1 - Composés organiques - Google Patents

Composés organiques

Info

Publication number
MA31798B1
MA31798B1 MA32804A MA32804A MA31798B1 MA 31798 B1 MA31798 B1 MA 31798B1 MA 32804 A MA32804 A MA 32804A MA 32804 A MA32804 A MA 32804A MA 31798 B1 MA31798 B1 MA 31798B1
Authority
MA
Morocco
Prior art keywords
organic compounds
modulator
parkinson
progression
disease
Prior art date
Application number
MA32804A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel Umbricht
Baltazar Gomez-Mancilla
Fabrizio Gasparini
Paolo Thérése Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31798B1 publication Critical patent/MA31798B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

L'INVENTION PORTE SUR L'UTILISATION D'UN MODULATEUR DE MGLUR, PAR EXEMPLE UN MODULATEUR DE MGLUR5, POUR LE TRAITEMENT, LA PRÉVENTION OU RETARDER LA PROGRESSION DE LA MALADIE DE PARKINSON ET DE TROUBLES ASSOCIÉS.
MA32804A 2007-10-12 2010-04-30 Composés organiques MA31798B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97948607P 2007-10-12 2007-10-12
US5033308P 2008-05-05 2008-05-05
PCT/EP2008/063544 WO2009047296A2 (fr) 2007-10-12 2008-10-09 Composés organiques

Publications (1)

Publication Number Publication Date
MA31798B1 true MA31798B1 (fr) 2010-10-01

Family

ID=40348021

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32804A MA31798B1 (fr) 2007-10-12 2010-04-30 Composés organiques

Country Status (19)

Country Link
US (2) US20100249136A1 (fr)
EP (1) EP2211859B1 (fr)
JP (2) JP5743545B2 (fr)
KR (1) KR101572280B1 (fr)
CN (1) CN101854935A (fr)
AU (1) AU2008309621A1 (fr)
BR (1) BRPI0818560A2 (fr)
CA (1) CA2701853A1 (fr)
CL (1) CL2008003006A1 (fr)
IL (1) IL204954A0 (fr)
MA (1) MA31798B1 (fr)
MX (1) MX2010003913A (fr)
NZ (1) NZ584856A (fr)
RU (1) RU2508107C2 (fr)
SG (1) SG185293A1 (fr)
TN (1) TN2010000155A1 (fr)
TW (1) TW200924745A (fr)
WO (1) WO2009047296A2 (fr)
ZA (1) ZA201002423B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010014222A (es) * 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
MX2011001664A (es) * 2008-08-12 2011-03-25 Novartis Ag Procesos para la preparacion del metil-ester del acido 4-oxo-octahidro-indol-1-carbociclico y derivados del mismo.
WO2011035209A1 (fr) * 2009-09-17 2011-03-24 Vanderbilt Universtiy Analogues de benzamide substitué en tant que modulateurs allostériques négatifs mglur5, et leurs procédés de préparation et d'utilisation
US9085562B2 (en) 2011-03-03 2015-07-21 Vanderbilt University 6-alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
AU2012232711B2 (en) 2011-03-18 2016-04-28 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's Disease
GB201204962D0 (en) 2012-03-21 2012-05-02 Addex Pharmaceuticals Sa Pharmaceutical combination products for parkinsons disease
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
KR101749675B1 (ko) * 2015-07-20 2017-06-26 동국대학교 산학협력단 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
DK1196397T3 (da) * 1999-06-02 2006-01-02 Nps Pharma Inc Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE60222698T2 (de) * 2001-12-18 2008-06-19 Merck & Co., Inc. Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
US7105533B2 (en) * 2002-09-13 2006-09-12 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
WO2004069146A2 (fr) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Derives d'amide l-dopa et utilisations de ceux-ci
EP1667983A4 (fr) * 2003-09-23 2010-07-21 Merck Sharp & Dohme Modulateurs pyrazole de recepteurs de glutamate metabotropiques
CA2555402A1 (fr) * 2004-02-12 2005-09-01 Celine Bonnefous Amides bipyridyles en tant que modulateurs du recepteur-5 metabotropique du glutamate
WO2006094639A1 (fr) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Dérivés de pyridine-2-carboxamide en tant qu’antagonistes du mglur5
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
TW200801005A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
AU2006329007A1 (en) * 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
JP2010502664A (ja) * 2006-09-11 2010-01-28 ノバルティス アクチエンゲゼルシャフト 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体
MX2010014222A (es) * 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.

Also Published As

Publication number Publication date
US20100249136A1 (en) 2010-09-30
CL2008003006A1 (es) 2009-05-08
JP2011500529A (ja) 2011-01-06
KR101572280B1 (ko) 2015-11-26
BRPI0818560A2 (pt) 2019-09-24
US20150272929A1 (en) 2015-10-01
SG185293A1 (en) 2012-11-29
NZ584856A (en) 2012-12-21
MX2010003913A (es) 2010-04-27
IL204954A0 (en) 2010-11-30
JP2014240425A (ja) 2014-12-25
CA2701853A1 (fr) 2009-04-16
TN2010000155A1 (en) 2011-11-11
CN101854935A (zh) 2010-10-06
AU2008309621A1 (en) 2009-04-16
EP2211859B1 (fr) 2016-01-06
JP5743545B2 (ja) 2015-07-01
ZA201002423B (en) 2010-12-29
WO2009047296A2 (fr) 2009-04-16
EP2211859A2 (fr) 2010-08-04
RU2010118454A (ru) 2011-11-20
TW200924745A (en) 2009-06-16
RU2508107C2 (ru) 2014-02-27
WO2009047296A3 (fr) 2009-08-20
KR20100088136A (ko) 2010-08-06

Similar Documents

Publication Publication Date Title
MA31798B1 (fr) Composés organiques
FR19C1005I1 (fr) Nano-corps ameliores (tm) pour le traitement des troubles lies a l'agregation
MA31156B1 (fr) Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
EP2063882A4 (fr) Inhibiteurs de kinase pour la prévention ou le traitement d'une infection
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
FR2915102B1 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EP1601251A4 (fr) Compos s pour le traitement de troubles m taboliques
MA29316B1 (fr) Derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
FR2921795B1 (fr) Utilisation d'une souche de bifidobacterium,pour la preparation d'une composition destinee a la prevention et/ou au traitement de manifestations de type allergique
MA32506B1 (fr) Nouveaux composes
EP2307011A4 (fr) Utilisation d'isoindoles pour le traitement de troubles neurocomportementaux
TN2016000040A1 (fr) Inhibiteurs de porc2 et procedes pour leur utilisation
EP2120930A4 (fr) Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques
FR2907677B1 (fr) Utilisation d'un copolymere bloc polysiloxane/polyuree pour le traitement des cheveux
FR3084255B1 (fr) Souche de streptococcus thermophilus cnrz160 pour le traitement et la prevention de l'inflammation intestinale et des desordres associes, chez un individu
WO2007120605A3 (fr) Traitement d'une maladie pulmonaire induite par la nicotine utilisant des agonistes gamma du recepteur active du proliferateur du peroxisome
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
EP1879616A4 (fr) Synthese de superanticorps et utilisation pour la detection, la prevention et le traitement de maladie
FR2907011B1 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
MA31369B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
EP2219447A4 (fr) Dérivés de s-alkylisothiouronium utilisés dans le traitement des troubles liés à l'hypercontractilité utérine
FR2915100B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
EP1868583A4 (fr) Compositions a liberation controlee comportant une celphalosporine pour le traitement d'une infection bacterienne
MA31368B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
FR2912059B1 (fr) Utilisation d'argiles pour le traitement de la maladie coeliaque